Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
- A. G. Robertson, Jaegil Kim, E. Zwarthoff
- BiologyCell
- 19 October 2017
Comprehensive molecular profiling of lung adenocarcinoma
- Eric A. Joshua D. Angela N. Alice H. William Juliann Da Collisson Campbell Brooks Berger Lee Chmielecki Be, Eric A. Joshua D. Angela N. Alice H. William Juliann Da Collisson Campbell Brooks Berger Lee Chmielecki Be, E. Duhig
- Biology, MedicineNature
- 1 July 2014
High rates of somatic mutation were seen, including RIT1 activating mutations and newly described loss-of-function MGA mutations which are mutually exclusive with focal MYC amplification, and MAPK and PI(3)K pathway activity was explained by known mutations in only a fraction of cases, suggesting additional, unexplained mechanisms of pathway activation.
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
- M. Imieliński, A. Berger, M. Meyerson
- BiologyCell
- 1 September 2012
Tuberous sclerosis.
- D. Kwiatkowski, M. Short
- MedicineArchives of Dermatology
- 1994
Identification of the two TS genes should illuminate the pathogenesis of TS and provide opportunities for genetic counseling, prenatal diagnosis, and therapeutic intervention.
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
- N. Agrawal, R. Akbani, L. Zou
- Medicine, BiologyCell
- 23 October 2014
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the…
- N. Lindeman, P. Cagle, M. Ladanyi
- MedicineJournal of Thoracic Oncology
- 1 July 2013
37 guideline items address 14 subjects, including 15 recommendations (evidence grade A/B), to use testing for EGFR mutations and ALK fusions to guide patient selection for therapy with an epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) inhibitor in all patients with advanced-stage adenocarcinoma.
LKB1 modulates lung cancer differentiation and metastasis
- H. Ji, M. R. Ramsey, Kwok-Kin Wong
- Biology, MedicineNature
- 16 August 2007
LKB1 is established as a critical barrier to pulmonary tumorigenesis, controlling initiation, differentiation and metastasis in lung cancer, and expression profiling in human lung cancer cell lines and mouse lung tumours identified a variety of metastasis-promoting genes as targets of LKB1 repression.
Comprehensive genomic characterization of squamous cell lung cancers
- P. Hammerman, Douglas Voet, R. Shen
- Biology, MedicineNature
- 6 September 2012
It is shown that the tumour type is characterized by complex genomic alterations, with a mean of 360 exonic mutations, 165 genomic rearrangements, and 323 segments of copy number alteration per tumour.
Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34.
- M. V. van Slegtenhorst, R. de Hoogt, D. Kwiatkowski
- Biology, MedicineScience
- 8 August 1997
Thirty-two distinct mutations were identified in TSC1, 30 of which were truncating, and a single mutation was seen in six apparently unrelated patients, which suggests that hamartin acts as a tumor suppressor.
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
- J. Campbell, A. Alexandrov, M. Meyerson
- Medicine, BiologyNature Genetics
- 28 April 2016
Although targeted therapies for lung ADC and SqCC are largely distinct, immunotherapies may aid in treatment for both subtypes.
...
...